Skip to main content

The LLS Blog

Read about survivors, research, fundraising and advocacy.

Meet The Researcher: Dr. Christopher R. Flowers

In this Q&A, we are highlighting Dr. Christopher R. Flowers, MD, chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center and LLS National Board Member. Later this week, Dr. Flowers will be speaking on a timely panel about diversity in hematology clinical trials at AACR 2021.

Because You Volunteer, Your Impact Creates a Ripple Effect

At The Leukemia & Lymphoma Society (LLS), volunteers are our superheroes. Learn about the impact our volunteers help make possible in honor of National Volunteer Week 2021. 

FDA Approval of New Treatment Option for Children with Secondary Acute Myeloid Leukemia is a Welcome Step Forward

Here at The Leukemia & Lymphoma Society (LLS), we applaud every advance for children with blood cancers.

FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma

Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017.

Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.

Older Posts